Has Richard Stefanic, MD received payments from drug or device companies?

Yes. Drug and device makers reported $664 in general payments to Richard Stefanic, MD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Stefanic, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Stefanic, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Stefanic, MD

General Practice · Reading, PANPI 1982955118

Payments from drug & device makers

$664in general payments, 2019–2025

Across 37 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$342
Alkermes, Inc.$149
Collegium Pharmaceutical, Inc.$40
Pfizer$35
Exact Sciences$25
Indivior Inc.$24
plus $50 from 3 others

What the payments were for

Food & beverage$664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	21	$342
Alkermes, Inc.	7	$149
Collegium Pharmaceutical, Inc.	2	$40
Pfizer	2	$35
Exact Sciences	1	$25
Indivior Inc.	1	$24
Genentech USA, Inc.	1	$20
Prescient Lab Services, LLC	1	$16
Supernus Pharmaceuticals, Inc.	1	$13

How this compares

$664 in reported general payments places this provider in the 80th percentile of 3,208 general practice providers in Pennsylvania.

See all general practice providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$18,484

Medicare patients

127

Services billed

223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	15	$23,939
FarxigaDapagliflozin Propanediol	24	$14,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	12	$11,672
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	14	$6,186
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	11	$1,647
Oxycodone Hcl	46	$1,402
Albuterol Sulfate HfaAlbuterol Sulfate	30	$865
Atorvastatin Calcium	31	$577
Rosuvastatin Calcium	57	$441
Levothyroxine Sodium	19	$274
Losartan Potassium	20	$239
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	22	$224
Tamsulosin Hcl	21	$222
Citalopram HbrCitalopram Hydrobromide	18	$176
Lisinopril	24	$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga	$342	$14,42724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,208 general practice providers in Pennsylvania.